The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Valieva Z.S.

Institut klinicheskoĭ kardiologii im. A.L. Miasnikova FGBU "Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks" Minzdrava Rossii, Moskva

Martynyuk T.V.

The Institute of Clinical Cardiology named after A.L. Myasnikov, Federal State Institution «National Medical Research Center of Сardiology», Moscow, Russia

Chazova I.E.

Federal State budget organization National Medical Research Center of Cardiology of the Ministry of healthcare of the Russian Federation, The Institute of Clinical Cardiology, Moscow, Russia

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience

Authors:

Valieva Z.S., Martynyuk T.V., Chazova I.E.

More about the authors

Journal: Therapeutic Archive. 2017;89(8): 95‑103

DOI: 10.17116/terarkh201789895-103

Read: 2363 times

Download PDF (RU)
Contact the author
Table of contents

BOSENTAN USE IN PULMONARY ARTERIAL HYPERTENSION: RUSSIAN AND FOREIGN EXPERIENCE
BOSENTAN USE IN PULMONARY ARTERIAL HYPERTENSION: RUSSIAN AND FOREIGN EXPERIENCE

To cite this article:

Valieva ZS, Martynyuk TV, Chazova IE. Bosentan use in pulmonary arterial hypertension: Russian and foreign experience. Therapeutic Archive. 2017;89(8):95‑103. (In Russ.)
https://doi.org/10.17116/terarkh201789895-103

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The results of evaluating the efficacy and safety of bosentan in patients with pulmonary arterial hypertension (PAH), as shown by the data of foreign randomized controlled trials and the authors’ own experience, convincingly demonstrate that the introduction of the drug into clinical practice has led to a significant improvement of the possibilities of drug therapy in patients with this serious illness. Bosentan substantially improves physical activity in patients, reduces the severity of clinical symptoms, slows down the rates of disease progression, and prolongs survival in patients with different forms of PAH.

Keywords:

pulmonary arterial hypertension
endothelin receptor antagonists
bosentan

Authors:

Valieva Z.S.

Institut klinicheskoĭ kardiologii im. A.L. Miasnikova FGBU "Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks" Minzdrava Rossii, Moskva

Martynyuk T.V.

The Institute of Clinical Cardiology named after A.L. Myasnikov, Federal State Institution «National Medical Research Center of Сardiology», Moscow, Russia

Chazova I.E.

Federal State budget organization National Medical Research Center of Cardiology of the Ministry of healthcare of the Russian Federation, The Institute of Clinical Cardiology, Moscow, Russia

Close metadata

References:

  1. Chazova IE, Avdeev SN, Tsareva NA, Volkov AV, Martynyuk TV, Nakonechnikov SN. on behalf of a Working Group on the Elaboration and Preparation of the Text of Russian Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevtičeskij arhiv. 2014;9:4-23. (In Russ.).
  2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier J-F, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen associated pulmonary arterial hypertension in the modern Management Era Circulation. 2010;122(2):156-163. https://doi.org/10.1161/circulationaha.109.911818
  3. Stewart DJ, Levy RD, Cernacek P. Increased plasma endothelin-1 in primary pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469. https://doi.org/10.7326/0003-4819-114-6-464
  4. Martynyuk TV, Masenko VP, Chazova IE, Belenkov Yu N. Endothelial dysfunction in patients with pulmonary hypertension. Kardiologiya. 1997;10:25-29. (In Russ.).
  5. Dupuis J, Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31:407-415. https://doi.org/10.1183/09031936.00078207
  6. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227-237. https://doi.org/10.1016/j.cardiores.2003.11.026
  7. Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med. 1996;154:555-584. https://doi.org/10.1164/ajrccm.154.3.8810589
  8. Clozel M, Breu V, Burri K, Cassal J-M, Fischli W, Gray GA, Hirth G, Löffier B-M, Müller M, Neidhart W, Ramuz H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759-761. https://doi.org/10.1038/365759a0
  9. Chen YF, Li H, Elton TS. The role of atrial natriuretic peptide and endothelin in hypoxia induced pulmonary hypertension. Chin J Physiol. 1994;37:165-183.
  10. Luscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions. 1995; 45,Suppl:237-253. https://doi.org/10.1007/978-3-0348-7346-8_34
  11. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:62S-67S. https://doi.org/10.1016/j.jacc.2004.02.042
  12. Stewart DJ. Endothelin in cardiopulmonary disease:factor paracrine vs neurohormonal. Eur Heart J 1993;14(SupplI):48-54.
  13. Russell FD, Davenport AP. Characterization of endothelin receptors in the human pulmonary vasculature using bosentan. J Cardiovasc Pharmacol. 1995;26(Suppl.3):S346-S351. https://doi.org/10.1097/00005344-199506263-00103
  14. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739. https://doi.org/10.1056/nejm199306173282402
  15. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J. 2008;29:1936-1948. https://doi.org/10.1093/eurheartj/ehn234
  16. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol. 1995; 26(Suppl.3):S262-S264. https://doi.org/10.1097/00005344-199526003-00079
  17. Chazova IE, Martynyuk TV, Masenko VP. The role of the lung in the metabolism of some markers of endothelial damage in normal and primary pulmonary hypertension. Kardiologiya. 2000;8:13-15. (In Russ.).
  18. Martynuk TV, Nakonechnikov SN, Chazova IE. Endothelium receptor antagonists in pulmonary arterial hypertension: yesterday, today, and tomorrow. Rossiiskii kardiologicheskii zhurnal. 2009;4:73-81. (In Russ.).
  19. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R, Crépeau J. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J. 1998;135:614-620. https://doi.org/10.1016/s0002-8703(98)70276-5
  20. Channick RN, Simonneau G, Sitbon O Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary artery hypertension:A randomized placebo-controlled study. Lancet. 2001;358:1119-1123. https://doi.org/10.1016/s0140-6736(01)06250-x
  21. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. The Cochrane Database of Systematic Reviews. 2004;Issue 4.Art.No.:CD004434. https://doi.org/10.1002/14651858.CD004434.pub2
  22. Galie N, Rubin LJ, Jansa P, Al-Hiti H, Meyer GMB, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):a double-blind, randomized, controlled trial. Lancet. 2008;371:2093-2100. https://doi.org/10.1016/s0140-6736(08)60919-8
  23. Chazov EI, Belenkov YuN Borisova EO, Gogin EE, Golitsin SP, Gurevich KG, Dashevskaya AM, Zolotukhin IA, Kirienko AI, Kukharchuk VV, Leonova MV, Luk’yanov SV, Mareev VYu, Martynyuk TV, Martsevich SYu, Mychka VB, Nasonov EL, Panchenko EP, Praskurnichii EA, Sidorenko BA, Susekov AV, Tyurin VP, Chazova IE, Yavelov IS. Ratsional’naya farmakoterapii serdechno-sosudistykh zabolevanii. Ruk. Dlya praktikuyushchikh vrachei. Izd. Literra, 2005. (In Russ.).
  24. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, Gatzoulis MA. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2009;121:20-25. https://doi.org/10.1161/circulationaha.109.883876
  25. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension:BREATHE-2. Eur Respir J. 2004;24:353-359. https://doi.org/10.1183/09031936.04.00028404
  26. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263. https://doi.org/10.1164/rccm.200603-358oc
  27. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903. https://doi.org/10.1056/nejmoa012212
  28. Martynyuk TV, Arkhipova OA, Kobal EA, Eruslanova KA, Danilov NM, Chazova IE. Use of the nonselective endothelin receptor antagonist bosentan in patients with idiopathic pulmonary hypertension: the first Russian experience and vision of the future. Sistemnye gipertenzii. 2011;4:51-57. (In Russ.).
  29. Paramonov VM, Martynyuk TV, Danilov NM, Matchin YuG, Chazova IYe. The results of long-term pah-specific monotherapy with bosentan in patients with idiopathic pulmonary hypertension. Evraziiskii kardiologicheskii zhurnal. 2016;2:48-57. (In Russ.).
  30. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24:1007-1010. https://doi.org/10.1183/09031936.04.00051104
  31. Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29:469-475. https://doi.org/10.1183/09031936.00081706
  32. Avdeev SN, Tsareva NA, Neklyudova GV, Chuchalin AG. First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study. Terapevticheskii arkhiv. 2013;3:38-43. (In Russ.).
  33. Volkov AV, Yudkina NN, Nikolaeva EV, Kurmukov IA, Glukhova SI, Nasonov EL. Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases. Terapevticheskii arkhiv. 2014;86(5):32-39. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.